Ademi LLP is investigating possible securities fraud claims against R1 (Nasdaq: RCM). The investigation results from inaccurate statements R1 may have made regarding its business operations and prospects.
The investigation focuses on whether R1 properly disclosed that it was experiencing (i) lower incentive fee revenue due to longer payer reimbursement turn-around times, (ii) lower net operating fees due to weaker volumes from emergency department physician customer, and (iii) financial challenges from one of R1’s emergency department customers.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.